Risankizumab in severe asthma: A Phase IIa, placebo-controlled study
C. Brightling (Leicester, United Kingdom), P. Nair (Hamilton, Canada), R. Louis (Liege, Belgium), D. Singh (Manchester, United Kingdom)
Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Brightling (Leicester, United Kingdom), P. Nair (Hamilton, Canada), R. Louis (Liege, Belgium), D. Singh (Manchester, United Kingdom). Risankizumab in severe asthma: A Phase IIa, placebo-controlled study. 3699
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007
Umeclidinium in patients with COPD: a randomised, placebo-controlled study Source: Eur Respir J 2014; 43: 72-81 Year: 2004
Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial Source: International Congress 2016 – Asthma management Year: 2016
Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019
Substitution of vitamin D in patients with moderate to severe persistent asthma: A randomized, placebo-controlled pilot study Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007
Recombinant human deoxyribonuclease (rhDNase) for the treatment of acute asthma in children: a multicentre randomised double-blind clinical trial Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007
A double-blind, randomized, sham-controlled study of Targeted Lung Denervation in patients with moderate to severe COPD Source: International Congress 2018 – Interventional pulmonology highlights in 2018: ELVR, TLD and BT Year: 2018
Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022
Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021